High Growth Tech Stocks To Watch In The US April 2025

Over the last 7 days, the United States market has dropped 3.4%, yet it remains up by 6.1% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and resilience amidst fluctuating market conditions.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 236 stocks from our US High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

Soleno Therapeutics (NasdaqCM:SLNO)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics for treating rare diseases, with a market cap of $3.30 billion.

Operations: Soleno Therapeutics focuses on developing and commercializing therapeutics for rare diseases. The company is in the clinical stage, indicating it is still in the process of bringing its products to market.

Soleno Therapeutics recently celebrated a significant milestone with the FDA's approval of VYKAT XR for treating Prader-Willi syndrome, an achievement reflecting its innovative edge in specialized pharmaceuticals. Despite a challenging financial backdrop marked by a substantial net loss increase to $175.85 million from the previous year and ongoing shareholder dilution, Soleno's strategic filings and robust clinical program underscore its commitment to growth and patient support. The company's revenue is projected to surge by 50.1% annually, outpacing the broader U.S. market forecast of 8.3%, positioning it as a potentially transformative player in biotech, pending its anticipated profitability within three years.

• Take a closer look at Soleno Therapeutics' potential here in our health report.

• Examine Soleno Therapeutics' past performance report to understand how it has performed in the past.

Verra Mobility (NasdaqCM:VRRM)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Verra Mobility Corporation provides smart mobility technology solutions and services across the United States, Australia, Europe, and Canada, with a market cap of $3.22 billion.

Operations: The company generates revenue through three main segments: Commercial Services ($407.68 million), Government Solutions ($390.90 million), and Parking Solutions ($80.62 million).

Verra Mobility, with a focus on fleet management and tolling solutions, recently partnered with Verizon Connect, enhancing its service offerings through integrated vehicle software solutions. This collaboration is expected to streamline operations for fleet managers by leveraging real-time data analytics. Despite facing challenges such as a significant net loss of $66.66 million in the last quarter of 2024 and ongoing high debt levels, Verra Mobility's strategic partnerships and innovative services are pivotal in maintaining its competitive edge in the tech-driven transportation sector. The company also repurchased shares worth $177.03 million last year, signaling confidence in its financial strategy despite the setbacks.

• Get an in-depth perspective on Verra Mobility's performance by reading our health report here.

• Gain insights into Verra Mobility's historical performance by reviewing our past performance report.

AbbVie (NYSE:ABBV)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: AbbVie Inc. is a research-based biopharmaceutical company involved in the global research, development, manufacture, commercialization, and sale of medicines and therapies with a market cap of $363.15 billion.

Operations: AbbVie focuses on the research, development, and sale of innovative medicines and therapies, generating $56.33 billion in revenue from these segments.

AbbVie's recent showcase at the AACR Annual Meeting 2025 underlines its commitment to advancing oncological treatments through innovative antibody-drug conjugates like ABBV-969 and targeted antibodies such as ABBV-514, which are in early-phase trials for challenging cancers. These developments reflect a strategic focus on high-stakes areas of medicine where significant unmet needs exist, potentially enhancing AbbVie’s long-term growth trajectory in biopharmaceuticals. Moreover, the company's emphasis on identifying novel biomarkers and treatment resistance mechanisms could set new standards in precision medicine, aligning with broader industry trends towards tailored therapies.

• Dive into the specifics of AbbVie here with our thorough health report.

• Understand AbbVie's track record by examining our Past report.

Next Steps

• Unlock our comprehensive list of 236 US High Growth Tech and AI Stocks by clicking here.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com